Uppsala, Sweden – Oktober 26, 2020 – As previously communicated Orexo will announce the Interim Report for Q3 2020, on Wednesday, November 4 at 8.00 am CET. The same day at 2.00 pm CET analysts, investors and media are invited to attend a presentation where Nikolaj Sørensen, CEO, and Joseph DeFeo, CFO, will present the report. After the presentation a Q&A will be held. Questions can also be sent in advance to firstname.lastname@example.org, no later than 11.00 am CET.
Please view the instructions below on how to participate:
Video link: https://financialhearings.com/event/12771
Telephone no. to attend the Q&A: SE: +46 566 42 651, UK: +44 333 300 90 31 US: +1 833 526 83 97
Prior to the event the presentation material will be available on Orexo´s website.
For further information, please contact:
Orexo AB (publ.)
Lena Wange, IR & Communications Director
Tel: +46 18 780 88 00
Develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercialize its lead product ZUBSOLV® for treatment of opioid use disorder. Total net sales for 2019 amounted to SEK 844,8 million and the number of employees was 127. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where research and development is also performed, is situated in Uppsala, Sweden.
For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.